Chang

Hemmie Chang

Partner
Co-Chair, Life Sciences Industry Group; Chair, Licensing & Strategic Alliances Practice
Boston

I help leading life sciences companies develop and commercialize their innovative IP assets around the globe.

As Chair of Foley Hoag's Licensing & Strategic Alliances Practice, Hemmie Chang regularly advises clients on high profile intellectual property transactions. Her career-spanning dedication to clients and significant influence on the life sciences industry earned her an induction into the LMG Life Sciences Hall of Fame in 2019, as well as recognition as a USA Top Women Dealmaker Awards, hosted by the Global M&A Network in 2022.

Clients routinely benefit from Hemmie's strategic business perspective and legal acumen from her two-plus decades of experience within the biopharmaceutical, medical device, diagnostics, gene and cell therapy and genomics sectors. She advises both established and emerging companies on a wide variety of licensing matters, from development to marketing deals - all of which involve a broad range of intellectual property assets, from patents and trade secrets to trademarks and copyrights. Hemmie has closed more than $20 billion in deals across diverse therapeutic areas opposite major pharma and biotech partners such as AbbVie, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, F. Hoffman-La Roche, Janssen Biotech, Merck, Novartis, Novo Nordisk and Takeda. 

Education

  • Harvard Law School, J.D.
  • Princeton University, A.B. (Princeton School of Public and International Affairs)

Bar and Court Admissions

BAR ADMISSIONS
  • Massachusetts
  • District of Columbia
  • Practicing Solicitor, England and Wales

Experience

Represents clients in collaborations, licensing transactions and investments with major pharmaceutical and emerging high-growth companies, and successfully counsels clients on investments, mergers and acquisitions and financings in energy and renewables (solar, wind) and other projects, including:
  • HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company with expertise in immune modulation and single cell science, in an agreement to exclusively license its Galectin-9 program, and grant an exclusive option to its CXCR5 and CCR8 programs, to biopharmaceutical company FibroGen, Inc. (Nasdaq: FGEN)
  • Genevant Sciences in its global collaboration and license agreement with Takeda Pharmaceutical Company Limited (NYSE: TAK) for the discovery, development and commercialization of LNP-delivered nucleic acid therapeutics directed to previously inaccessible drug targets in hepatic stellate cells to treat liver fibrosis
  • H.I.G. BioHealth Partners and Accelmed Partners as new investors and co-leads in the $52 million upsized Series B financing of digital therapeutics company Click Therapeutics 
  • Windgap Medical, a developer of auto-injectors and drug delivery devices designed to treat patients with severe allergies, in multiple transactions, including:
    • its $39 million Series B-1 equity financing led by Taiwania Capital
    • its strategic partnership with Danish allergy immunotherapy biotech ALK-Abell√≥ to commercialize the company's epinephrine autoinjector for the treatment of anaphylactic shock
    • its Series A financing led by GRT BioEdge Ventures
  • LegoChem Biosciences (KOSDAQ: 141080) in numerous collaboration agreements, including:
    • a $300 million licensing agreement with Pyxis Oncology for the development and sales of LCB67, an investigational antibody drug conjugate, for the high unmet need in advanced solid cancer treatment 
    • a global licensing agreement with Cstone Pharmaceuticals (HKEX: 2616) for the development and commercialization of LCB71, a potential first-in-class/best-in-class antibody drug conjugate, for $363.5 million in upfront, milestone and tiered royalty payments
    • two collaborations with Iksuda Therapeutics totaling over $625 million in development, regulatory and commercial milestone payments: (i) a research collaboration and license agreement for the development of antibody-drug conjugates in oncology, (ii) a global license agreement for the development and commercialization of LCB73, a CD19-targeted ADC candidate for hematological tumors
    • a $400+ million multi-target research collaboration and license agreement with Takeda Pharmaceutical Company Limited
  • Dicerna Pharmaceuticals (Nasdaq: DRNA) in numerous agreements, including:
    • a global collaboration agreement with Novo Nordisk A/S to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases for an upfront payment of $175 million, a $50 million equity investment and up to $357.5 million per target in development, regulatory, and commercialization milestone payments
    • a global collaboration and license agreement in excess of $1.67 billion in upfront and milestone payments, plus royalties, with F. Hoffmann-La Roche AG to develop and commercialize DCR-HBVS for the treatment of chronic Hepatitis B Virus (HBV) infection
    • three collaborations totaling over $4.5 billion in potential deal value and $250 million in upfront and equity investments: (i) global licensing and research collaboration with Eli Lilly focused on potential new medicines in the areas of cardio-metabolic disease, neurodegeneration and pain; (ii) collaboration with Alexion Pharmaceuticals to discover and develop RNA interference therapies for complement-mediated diseases; and (iii) research deal with Boehringer Ingelheim to discover and develop novel GalXC™ RNAi therapeutics for the treatment of chronic liver diseases, initially nonalcoholic steatohepatitis (NASH)
  • Bridge Biotherapeutics in a collaboration and license agreement in excess of €1.1 billion in upfront and milestone payments, plus royalties, with Boehringer Ingelheim to develop Bridge Biotherapeutics’ autotaxin inhibitor BBT-877 for idiopathic pulmonary fibrosis (IPF) and other fibrosing interstitial lung diseases. 
  • Alexion Pharmaceuticals (Nasdaq: ALXN) in a $650+ million collaboration peptide deal with Zealand Pharma 
  • LG Chem Life Sciences in a $900+ million multi-target, strategic collaboration announced in November 2018 with CUE Biopharma that provides LG Chem with the Asia rights to Cue Biopharma’s lead immuno-oncology CUE-101 program, and products in the two other CUE-102 and CUE-103 programs as well as a worldwide option for another antigen focused biologic
  • Korean pharmaceutical company Dong-A ST in its $525 million exclusive license agreement for the global development and commercialization of its investigational immuno-oncology drug Mer tyrosine kinase inhibitor (Mer TKI) with U.S. pharmaceutical company AbbVie
  • Genomics Medicine Ireland (GMI) in its 15-year partnership with pharmaceutical company AbbVie Ireland and WuXi NextCode to conduct population genomics research in Ireland and examine potential genetic triggers for major chronic diseases. GMI's investors included ARCH Venture Partners, Polaris Partners, GV (formerly Google Ventures), the Ireland Strategic Investment Fund, and corporate partner Amgen and its subsidiary deCODE genetics
  • Pear Therapeutics in its collaboration with Novartis using Pear’s first-ever FDA cleared software application as digital therapeutics in treating schizophrenia and multiple sclerosis 
  • Clinical-stage pharmaceutical company Calithera Biosciences on the IP aspects of its global license agreement with Incyte, granting Incyte exclusive rights to research, develop and commercialize TransTech's portfolio of hexokinase II inhibitors
  • U.K.-based biopharmaceutical company PrEP Biopharm Limited in a £21 million (approximately US$32 million) Series A financing round, led by a large publicly traded U.K. clinical research organization and top pharma venture investor, to complete development of a compound designed to help patients with respiratory viral infections in-licensed from the pharma investor’s affiliate
  • Chromocell Corporation in its collaboration and licensing agreement with Astellas Pharma. to develop and commercialize new therapies to treat neuropathic pain for upfront and milestone payments exceeding $500 million, plus royalties
  • Applied Genetic Technologies Corporation (Nasdaq: AGTC) in various deals, including:
    • its $1+ billion collaboration with equity investment and manufacturing agreements with Biogen (NASDAQ: BIIB), one of the largest publicly announced gene therapy deals
    • its initial public and follow on offerings of common stock raising over US $80 million, after previously completing a $37.5 million Series B financing with Alta Partners, S.R. One, InterWest Partners, MedImmune Ventures and Intersouth Partners
  • Microchips Biotech, Inc. in a $35 million upfront partnership with Teva Pharmaceutical Industries Ltd., under which the companies will explore ways to apply Microchip Biotech's implantable drug delivery device to Teva’s line of products
  • NextCODE Health (organized by deCODE/AMGEN founders, ARCH and Polaris) in its sale of its wholly-owned operating subsidiary, NextCODE Health Luxembourg, S.a.r.l. to WuXi Genomics
  • OliPass Corporation, a biopharmaceutical company focused on developing antisense medicines based on peptide nucleic acid (PNA) technology, in its strategic partnership with Bristol-Myers Squibb Company (NYSE: BMY)
  • Medical diagnostics company Alere Inc. (NYSE: ALR) on licensing and intellectual property matters in its $600 million sale of the Alere Health division to healthcare company Optum
  • Alopexx and Inventages (Nestl√©’s venture capital arm) in $15.6M Series D financing of emerging medical device company Cognoptix (formerly Neuroptix Corporation), targeting the early detection of Alzheimer's disease
  • Good Start Genetics in a collaboration agreement for prenatal and other tests with PerkinElmer
  • Zosano Pharma in its agreement with Novo Nordisk A/S to develop a new transdermal presentation of semaglutide
  • Living Proof in its global venture with Valeant Pharmaceuticals International, Inc. to develop, distribute and commercialize products for aesthetic dermatology
  • NextCODE Health with securing an exclusive license for sequence-based clinical diagnostic applications using technology developed by deCODE genetics, and also with securing $15 million in Series A financing from Polaris Partners and ARCH Venture Partners
  • High Performance Optics in its exclusive and global license agreement with Essilor
  • Metamark Genetics-Janssen Biotech in an early stage discovery collaboration deal in cancer - the largest at the time (up to $365 million in milestone payments)
  • Worked on the development and supply agreement of robotic surgical instruments for the U.S. subsidiary of a major Japanese conglomerate.
  • Crafted an early stage discovery and equity investment biofuels deal with a major European partner
  • Arisaph Pharmaceuticals in a major reset of royalty and other payments to monetize $26.25 million in upfront and ongoing payments from Royalty Pharma
  • Bioneer, a Korean public biotech, in a siNRA research collaboration with Sanofi
  • Worked on the Translational Therapeutics Inc.-Clavis Pharma, Inc. oncology candidate in-license (named BioWorld International Deal of the Week; May 2011)
  • Spinoff of assets (e.g. Bayer Healthcare oncology assets programs, IntElect Medical deep brain stimulation technology from one of the top five U.S. ranked hospitals)
  • Advised on early stage development deals for NYU spinoff with Medtronic, NuVasive and Stryker, agreements with Life Technologies and Illumina and option and development deals with GlaxoSmithKline, Sanofi and research collaboration with AstraZeneca
  • Advise on numerous academic licenses from Harvard, MIT, Massachusetts General Hospital, Johns Hopkins and UCSF

PROFESSIONAL EXPERIENCE
  • Biotechnology Industry Organization, Moderator and Speaker
  • Licensing Executives Society, Moderator and Speaker
  • Massachusetts Biotechnology Council, Faculty
  • Massachusetts Continuing Legal Education, Faculty

Publications

Honors & Involvement

HONORS
  • Named a USA Top Women by the Global M&A Network (2022)
  • Named a “Go-To Lawyer” for Life Sciences by Massachusetts Lawyers Weekly (2022)
  • Named a Top Woman of Law by Massachusetts Lawyers Weekly (2020) 
  • Inducted into the LMG Life Sciences Hall of Fame (2019) 
  • Listed in New England Super Lawyers Magazine (2013, 2014)
  • Articles Editor, Harvard Law Review
  • Phi Beta Kappa, Princeton University
INVOLVEMENT
  • Represent the Asian American Legal Defense and Education Fund (AALDEF) in the U.S. Supreme Court, U.S. Court of Appeals (First Circuit) and U.S. District Court (D. Mass.) in support of affirmative action in the Harvard case
  • Represented AALDEF in filing an amicus brief in U.S. Supreme Court on behalf of 21 Asian American groups and 44 higher education faculty and officials to uphold the University of Texas at Austin’s freshman affirmative action admissions policy. A 4-3 majority decision was reached in June 2016 to uphold the policy, which was in its second round of litigation before the nation’s highest court. 
  • South Cove Manor, Nursing & Rehabilitation Center, Inc. and South Cove Nursing Facilities Foundation, Board Member and Secretary
  • Franklin Square House Foundation, Board Member
  • National Asian Pacific American Bar Association (NAPABA), Member
  • The Commonwealth of Massachusetts Advisory Group on Undergraduate Education, Member
  • Asian American Lawyers Association of Massachusetts, Founding Director
  • Asian Task Force Against Domestic Violence, Founding Director

Speaking Engagements

  • “Navigating Asia-Pacific Innovation Deal Opportunities,” BIO International Convention (June 2022) 
  • "The Next Big Deal: Market Outlook for 2021 and Beyond," BIO International Convention (June 2021) 
  • “The Future of Immuno-Oncology Deal Making,” BioNetwork Partnering Summit (October 2019) 
  • “What’s Next in Immunology Deal Making,” BioNetwork Partnering Summit (October 2018)
  • "New Venture Competition Legal Series: Intellectual Property and Strategic Licensing," Harvard Business School (February 2017) 
  • "Licensing Trends: What’s New/What’s Hot?," Boston Bar Association Life Sciences Conference (November 2016) 
  • "Strategic Alliances and Joint Ventures," New England Mass Forum (October 2016) 
  • "Current and Future Opportunities in Gene and Cell Therapies," Bio Network West (October 2016) 
  • "Top U.S. Licensing & Regulatory Issues," Korea-US Cooperative Conference for Life Science (September 2016)
  • "Exploring the Latest Innovative Deal Structures and the Evolution of Traditional Licensing and M&A," Bio Network East (May 2016)
  • "A Day in the Life of the Office of the Corporate Secretary," NAPABA Northeast Regional Conference (October 2015)
  • “Assessing Value and Translating Priorities into Deal Terms,” (LES) 50th Anniversary Annual Meeting (October 2014)
  • “Exploring Alternative Sources of Early Stage Funding,” BioNetwork West (October 2014)
  • “How to Structure and Negotiate Deals in the U.S. for the Best Economic and Legal Results,” BIO International (June 2014)
  • "Entering the U.S. Healthcare Market," presentation for Korean Biopharmaceutical Companies (May 2014)
  • "Licensing Boot Camp: Intellectual Property & the Business of Biotech," Endicott College (March 2014)
  • "Creating Successful Life Sciences Partnerships," Massachusetts Continuing Legal Education (MCLE) (February 2014)
  • "Licensing Both Ways: Advancing Developments Today While Preserving Rights Tomorrow," Greentown Labs (August 2013)
  • "Exploring Opportunities to Strengthen Your Patent Portfolio Through Licensing," American Conference Institute’s 4th Advanced Summit on Biosimilars (June 2013)
  • "Innovation California Style: How are West Coast Companies Getting from Bench to Product," Licensing Executives Society (LES) Spring Meeting (May 2013)
  • "Can You Reap What You Sow? How the Necessity of Acquiring Early-Stage Assets Can Also Be Win-Win," BIO International (April 2013)
  • "Breaking Down the Tenets Of A True Early-Stage Partnership," BioNetwork East (April 2013)
  • "The Current State of Healthcare & Bioscience Venture Capital, Private Equity & M&A Activity," New England Healthcare Executive Network (NEHEN) (November 2012)
  • “Option to License Deals: finding a Winning Balance,” Licensing Executives Society (LES) Annual Meeting (October 2012)
  • “Partnering a Platform Technology Today When Companies Want a Drug Tomorrow,” BioNetwork West (October 2012)
  • “What’s New in Licensing: America Invents Act and Other Recent Developments,”  BioWorld.com Webinar (September 2012)
  • “Sunbeam Products: New Case Law for Trademarks in Bankruptcy TeleBriefing,” Law Seminars International Webinar (September 2012)
  • “Corporate Partnering deals and other non-equity sources of capital (including gov’t grants),” MassChallenge Panel (August 2012)
  • “Licensing Back to the Future: Understanding Option Licenses to Advance Developments Today While Preserving Rights Tomorrow,” BIO International (June 2012)
  • “Finding the Right Time to Partner: Can you Maximize Value While Balancing Risk and Reward?,” Licensing Executives Society (LES) Spring Meeting (May 2012)
  • “Perspectives of Innovative Small Companies on the Industry’s Prospects for 2012 and Beyond,” American Conference Institute (ACI) (February 2012)